Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why This Gene-Therapy Company's Stock Is Rising 228%
Poseida Therapeutics, a cell therapy company, is being acquired by Roche in a $1.5 billion deal.
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates
Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to loss of $0.35 per share a year ago.
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Poseida Therapeutics shows promising early results in myeloma with their BCMA-directed allogeneic CAR T-cell therapy, achieving a 60% response rate in phase 1 trials. Financially stable with $30.5 million in cash, $207.3 million in short-term investments, and a $20 million milestone payment from Roche extending their cash runway. Strong partnerships with big pharma and deep cash reserves provide a solid foundation for continued development and potential non-dilutive funding.
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.32 per share a year ago.
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
